fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

June Markets Kick Off Positively Led By A Ridiculous Energy Sector Jump!

By John F. Heerdink, Jr.
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

Happy Saturday All!

I hope that all of you had a great week investing and trading in the markets. It was a generally positive week that saw June ring in another positive week in 2021. The major indices rose week-over-week across the board.  The Dow 30 closed at 34,756.39 (+.7%) for the week & is now up +13.6% YTD & the S&P 500 closed at 4,229.89 (+.6%) for the week and is now up +12.6% YTD. The Nasdaq closed at 13,814.49 (+.5%) for the week and is now up +7.2% YTD. The small caps on the Russell 2000 closed at 2,286.41 (+.8%) for the week & are now up +15.8% YTD. The Microcaps also moved nicely higher again this week evidenced by the iShares Micro-Cap ETF (IWC), which closed at $151.92 up from the $149.58 close last week & nearing its 52-wk high of $159.56.  

Setting the overall positive tone, the energy sector gained a ridiculous 6.7% during the week and moving its YTD returns to an even more ridiculous +45.3%, which was powered by a +5% jump in oil prices the climbed to another ~3-year high $69.61/bbl. Dow 30 component Chevron (CVX) closed at $108.45, +.8% on Friday and is up from its 52-wk low of $65.16.

Also, setting the table for the markets this week was a resolution of sorts regarding corporate taxes where the G-7 (an informal group of seven of wealthy democracies consisting of Canada, France, Germany, Italy, Japan, the United Kingdom and the United States) neared an agreement on a 15% global minimum corporate tax.  The Biden administration also seemed to be pulling back from the irrational and proposed top corporate tax 28% rate & is now reportedly considering a 15% minimum tax rate.

MACRO/RATES/DOLLAR 

Many macroeconomic reports surfaced this week. On Tuesday, the ISM Manufacturing Index report for May confirmed a move up to 61.2% & has now finished well above the Mendoza line (50) for a year confirming continued expansion and that manufacturing is trying to get back on line to meet current demand. The total construction spending report also edged higher .2% month/month in April, while total private construction moved up .4% month/month. The total public construction spending report showed a drop by .6%. The final IHS Market Manufacturing PMI report for April came in at 62.1%. On Wednesday, the weekly MBA Mortgage Index report confirmed a drop by 4% while the Purchase Index report showed a drop by 3.1% & the Refinance Index report confirmed a 4.6% drop as well. The Fed’s June Beige Book confirmed that that the US economy expanded moderately between April and late May, but also sited appearance of shortages & moderate employment & wage growth.  On Thursday, the initial claims report for the week ending May 29 confirmed a drop by 20k to 385k as continuing claims for the week ending May 22 rose by 169k to 3.771M. This issue is believed to be associated with the unwillingness of eligible workers to head back to work with stimulus measures in place. The ADP Employment Change report confirmed that 978k private-sector payrolls were added in May. The ISM Non-Manufacturing Index report for May confirmed a rise to 64. The Final IHS Markit Services PMI report for May confirmed a rise to 70.4. Q1 Productivity remained at 5.4%, while Q1 unit labor costs were revised to +1.7%. On Friday, the May nonfarm payrolls report confirmed a rise by 559k below the expected 720k. April nonfarm payrolls were revised up to 278k. March nonfarm payrolls were revised up to 785,000. May private sector payrolls rose by 492k. April private sector payrolls were revised up to 219k. March private sector payrolls were revised up to 724k. May unemployment rate came in at 5.8% below expectations.  The U6 unemployment rate, come in at 10.2% blower than April. May average hourly earnings rose .5%. Over the last year, average hourly earnings have moved up 2%. The average workweek in May was 34.9 hours as expected.  The labor force participation rate came in at 61.6%. Factory orders for manufactured goods repot confirmed a drop by .6% month/month in April. Shipments of manufactured goods moved up .4%. Next week, we will receive number of reports which will include include the CPI report, the consumer credit report, & the hourly earnings report.

The yield curve lower this week as inflationary concerns drifted and investors seemed to understand that the FED will not be raising rates anytime soon based on their transitory position regarding inflation. The 10-yr yield fell 3 basis points wk/wk to close 1.554, while the 2-yr settled rose 1 basis point wk/wk close at .153%.

The U.S. Dollar Index also ticked slightly lower from 90.32 to 90.13. 

VISTA STORIES FROM THE DOW 30

The Coca-Cola Company Becomes The First Global Implementation Partner For The Ocean Cleanup’s River Project

Verizon Offering Offering free Apple & Android Phones To Sign Up For Unlimited 5G Plans

Chevron Allowed To Continue Restricted Operations In Venezuela

Merck & Sanofi Has Developed First Hexavalent Combination Vaccine Vaxelis™ In US

Russia Issues Warning To Disney Against Distribution Of Its Short Film “Out” Featuring Gay Character

CONSUMER – TECH 

Leading EV car maker Tesla (TSLA) moved lower this week to close at $599.05 & down $26.17/share from last Fridays’s $625.22 close as Elon Musk continued to ‘piss’ off cyptocurrency investors with his ongoing & recent negative Twitter rhetoric that he has ‘broken up’ with crypto and Bitcoin as he is concerned with the increased use of fossil fuels. Shares of Ford Motor Co (F) continued to surge this week closing at $15.97 and hit a new 52-wk high of $16.47. Last week, Ford revealed their customer-focused strategic ambitions and actions in a virtual meeting with financial analysts and other stakeholders during an event themed “Delivering Ford+”. Ford CEO Jim Farley stated, “We will deliver lower costs, stronger loyalty and greater returns across all our customers. This is our biggest opportunity for growth and value creation since Henry Ford started to scale the Model T, and we’re grabbing it with both hands.” Ford expects 40% of Ford global vehicle volume to be all-electric by 2030 & raised planned electrification spending to $30+ billion by 2025, including development of IonBoost batteries.

ADT (ADT), the “most trusted brand in smart home and small business security” and Google partner closed at $11.04 up again from last Friday’s close of $10.34. On August 3, 2020, ADT and Google announced a partnership to create ‘Leading Smart Home Security Offering’. The partnership has allowed Google’s award-winning Nest hardware to be combined with ADT’s trusted security, professional installation and monitoring service to create a fully integrated set of devices, software and services for the secure smart home & pairs ADT’s more than 20,000 professionals together with Google’s suite of helpful home hardware, manufacturing technology and vertical technology stack. Google also invested $450 million to acquire 6.6% ownership in ADT, cementing mutual, long-term commitment to partnership. Each company is to commit $150 million for co-marketing, product development, technology and employee training. This partnership is believed to provide customers with integrated smart home technology to be offered in both DIY and professionally installed security offerings.

Cathie Wood’s ARK Innovation ETF slipped this week as it closed at $109.51 down from last Friday’s close of $112.10 & well off her 52-wk high of $159.70. 

BIOTECH ‘FOUND MORE GROUND’ THIS WEEK

The Biotech sector found a little more ground this week as a number of issues moved forward. The Nasdaq Biotechnology ETF (IBB) closed at $153.02 up from last week’s Friday close of $151.95. The NYSE ARCA Biotech Index (^BTK) closed at 5,556.63 slightly down from last week’s close of 5,572.71. The SPDR S&P Biotech ETF (XBI) closed at $126.76 down last Friday’s close $128.10. The XBI’s 52-wk range is $97.15-$174.79 and had been getting hit harshly since the early part of March!

On Monday, June 7th the U.S. Food and Drug Administration is expected to decide whether to approve Biogen’s (BIIB) Alzheimer’s disease (AD) therapy, aducanumab. The news will likely have significant implications for patients & Biogen, but it will also be important for all companies developing therapies for AD. many believe that Biogen’s aducanumab is not the complete answer even if it gets approved, but if it gets appoved or not, this event will most definitely shine significant light on the disease state and all companies in the space alike. Did you know that +6 million Americans have Alzheimer’s disease and that number is growing?… If you have not checked out our VP Watchlist company INmune Bio (INMB, $13.56) and their focused work on modulating components of the innate immune system to activate an immune response against cancer and Alzheimer’s disease, then please do so now at this link. This week, INmune Bio, Inc. (NASDAQ: INMB), confirmed via announcement that the United States Adopted Name Council (USAN) has adopted the name “Pegipanermin” for its lead clinical candidate, XPro1595.  The United States Adopted Names (USAN) Council is responsible for selecting simple, informative and unique nonproprietary (generic) drug names. The council and staff meet twice a year to discuss outstanding negotiations, new items of interest and policy issues. The USAN Council establishes logical nomenclature classifications based on pharmacological and/or chemical relationships. In addition to one member-at-large and a Food and Drug Administration (FDA) liaison, the council consists of one representative from each of the following: The American Medical Association (AMA), United States Pharmacopeia (USP) and the American Pharmacists Association (APhA).

Please do not miss this coming Wednesday, June 9th’s Tribe Public Presentation & Q&A Event titled “Discussion of Atossa’s Final Data from its Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery.”  I will be hosting Atossa Therapeutics’ (NASDAQ: ATOS, $4.62) CEO Dr. Steven C. Quay, M.D., Ph.D., CFO Kyle Guse, & B. Heather Fraser, Ph.D. VP Clinical, Regulatory & CMC. Tribe events are efficient and approximately 30 minutes in duration and afford you to learn more about the companies you care about and ask the questions that are on your mind. Pleaser register for this FREE event at ATOS.TribePublic.com. Shares of Atossa shares of have been on a torrid upward pace this year as it has moved up from a 52-wk low of $.81 to a high of $5.08 while trading 11.34M shares/day on average. Interest has grown around their programs in breast cancer, covid-19 and their world-class management team. Atossa now has an ~$558M market cap with ~$137.7 million in cash reported at the end of Q1/2021.

GOLD & SILVER MOVES LOWER

Gold prices closed back below $1900/oz this week closing at $1,894, down $13 from the $1,907 close last week. This Friday silver prices closed at $27.89/oz. down $.14 from the $28.03/oz. close last Friday. Hecla Mining (HL) recently reported impressive Q1 2021 financial and operating results recently and closed at $8.92 down from the $9 close last Friday after establishing a new-52-wk high of $9.44 this week.  See our update story here for greater details.

MEMESTOCKS 

MemeStock, AMC Entertainment (AMC), closed at $47.91 after +95.22% move on Wednesday and the stock hitting a new 52-week high of $72.62. On Thursday, AMC announced that it had completed another 11.55M share at-the-market (“ATM”) equity program. AMC raised approximately $587.4M of new equity capital, before commissions and fees, at an average price of approximately $50.85 per share. AMC President and CEO Adam Aron said, “Bringing in an additional $587.4 million of new equity on top of the $658.5 million already raised this quarter results in a total equity raise in the second quarter of $1.246 billion, substantially strengthening and improving AMC’s balance sheet, providing valuable flexibility to respond to potential challenges and capitalize on attractive opportunities in the future.” Earlier in the week AMC also announced that it had entered into an agreement to raise $230.5 million of cash from the sale of equity to Mudrick Capital Management, L.P. in exchange for 8.5 million shares of AMC’s Class A Common stock. The equity was raised at a price of approximately $27.12 per share.  

GameStop (GME) also closed at $248.36, -3.8% on Friday.

Bed Bath & Beyond (BBBY) closed at $31.71, -.6% on Friday but on Wednesday BBBY moved up a whopping 62.1% surge. They recently announced that they will launch three new Owned Brands this quarter, continuing the Company’s execution of its biggest product assortment change in a generation to rebuild its authority in the $180 billion home market. With the launch of the new Owned Brands in the coming weeks, the Company will have launched six Owned Brands in five months – which is ahead of its previously announced 6-month timetable and in advance of the important Back to College shopping season.

BlackBerry Limited (BB) continued+39.02% higher this week and closed at $13.86 on Friday.  Recently, BB announced that BlackBerry® Optics 3.0, its next-generation cloud-based endpoint detection and response (EDR) solution and BlackBerry® Gateway, the company’s first AI-empowered Zero Trust Network Access (ZTNA) product. Rooted in a prevention-first and AI-driven approach, BlackBerry’s new endpoint and network security capabilities will help differentiate BlackBerry’s extended detection and response (XDR) strategy.

TRADING

The markets will be back to normal next week with 5-day trading sessions. 


 
VP WATCHLIST UPDATES 
Please review our complete VP Watchlist here that includes a brief list of highlighted companies that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.
Below are updates for five of the emerging companies from the VP Watchlist. 

  • Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed at $16.81 up slightly from last week’s $16.50 close. Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs. 
    • On May 12, Chinook provided a business update and reported financial results for the first quarter ended March 31, 2021. Eric Dobmeier, president and chief executive officer of Chinook Therapeutics stated,  “During the first quarter of 2021, Chinook made strong progress with its pipeline of programs for kidney diseases, including initiating the phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, presenting encouraging clinical data from the BION-1301 program and entering into a strategic collaboration with Evotec. We are well-capitalized and resourced to execute across our programs to generate additional data catalysts and continue building Chinook into a leading kidney disease company.”

    • On April 15, Chinook’s CEO Eric Dobmeier  & CBO Tom Frohlich delivered a presentation titled “Revolutionizing The Treatment of Kidney Disease” followed by a Q&A session at the Tribe Public Network. You can view the video of the event here. 


  • INmune Bio, Inc. (NASDAQ: INMB) closed at $13.37 on Friday and up significantly since we added them recently in the $9 range. INMB is a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease. INMB is further focused on modulating components of the innate immune system to activate an immune response against cancer and Alzheimer’s disease. (52-wk range $4.50-$29.99).
  • INMB closed Q1/2021 with cash of $45.3M, which management believes is enough to fund operations into Q4/2022. Per our beliefs, INMB’s biggest value generator is its Phase 1 AD program, with additional results due later this year and their Phase 2 to start in in the 2nd half of this year. Keep an eye INMB around June 7th with Biogen (BIIB) is to receive a ‘go” or a ‘nogo” from the FDA for their Alzheimer’s Drug as it is likely to shine a positive light INMB’s program and others in the space as focus is increased on AD via this outcome positive or negative.
    • INmune Bio’s DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
    • On May 18th, I hosted Immune Bio’s CEO RJ Tesi at the Tribe Public Presentation & Q&A Event for a fascinating discussion and his presentation titled “Advancing Treatment To Repair Our Aging Innate Immune System to Fight Alzheimer’s.” Please view the event video here. 
    • On May 5th, INMB reported its financial results for the first quarter ended March 31, 2021 and provided a business update on Wednesday, May 5th. RJ Tesi, M.D., chief executive officer of INmune Bio stated, “We continued to treat patients in the Phase I XPro1595 Alzheimer’s disease trial and expand the extensive biomarker data. The interim data that we reported in January confirms that XPro1595 decreases neuroinflammation in patients with Alzheimer’s disease and supports transitioning to a blinded randomized placebo-controlled Phase II trial later this year. We regard these results as extremely promising and look forward to further confirmation of XPro1595’s potential benefit to these patients in a rigorously designed Phase 2 study. We will report the additional biomarker data later this Summer. We have started screening patients in the Phase I INKmune NK cell priming platform trial in patients with high-risk myelodysplastic syndrome (MDS). MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells, and approximately one-third of cases progress to AML. We created a short 5-minute video that we believe does a wonderful job explaining why NK cells fail to clear cancer and how the cellular and molecular interactions by INKmune activate NK cells to kill resistant tumors. The video can be found by clicking here.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $72.79, +8.24% on Friday, but down from last Friday’s close of $76.60. 
    • On May 13th, Fate announced encouraging interim Phase 1 data from the Company’s off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML). The ongoing Phase 1 dose-escalation study of FT516 as monotherapy is currently enrolling patients in the third dose cohort (900 million cells per dose), with three patients treated in the first dose cohort (90 million cells per dose) and six patients treated in the second dose cohort (300 million cells per dose). The Phase 1 dose-escalation study of FT538 as monotherapy is currently ongoing, with three patients treated in the first dose cohort (100 million cells per dose). Learn more. 
    • On May 5th, Fate reported their business highlights and financial results for the first quarter ended March 31, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “During the first quarter of 2021, we strengthened our balance sheet by raising $460 million and successfully positioned our off-the-shelf, iPSC-derived NK cell pipeline to achieve significant clinical milestones across our disease franchises throughout the remainder of the year. We look forward to sharing Phase 1 clinical data from our FT516 and FT538 programs in relapsed / refractory AML at an investor event to be held alongside the ASGCT conference. We are also pleased with the clinical expansion of our FT538 program into solid tumors, where we plan to combine with FDA-approved monoclonal antibodies targeting EGFR, HER2, and PDL1. While we are disappointed that the PROTECT study of ProTmune did not meet its primary endpoint for prevention of acute graft-versus-host disease following allogeneic stem cell transplant, we will now turn our full attention and resources to our deep pipeline of off-the-shelf, iPSC-derived cancer immunotherapies. We would like to sincerely thank the patients, caregivers and investigators who participated in the clinical investigation of ProTmune, and we intend to share our clinical findings with that community.”

    • In related news, we have made another investment in a private NKcell company called Cytovia Therapeutics, a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies.  Their website is www.cytoviatx.com. This week, Cytovia announced  that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately. In addition, to support the rapid development of the company, Elizabeth Schwarzbach, PhD and Boris Reznik, PhD have joined the Strategic Advisory Board and Elysa Mantel has been appointed as Vice President, General Counsel and Corporate Secretary. Cytovia is seeking to go public in the 2H 2021.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $4.62 up from last Friday’s close of $3.22 Friday and is trading 11.24M shares a day.
    • This week, Physician-Scientist Dr. Steven C. Quay, M.D., Ph.D., CEO of Atossa Therapeutics (NASDAQ: ATOS) was asked to brief the elected members and staff of the United States Congress on his work on the origin of the COVID-19 pandemic. The virtual meeting was scheduled for Monday, May 24, 2021. Dr. Quay was too speak about his research on the origin of the pandemic, which he published in January 2021 and which is available here. In this analysis he concludes that it is beyond a reasonable doubt the virus came from a laboratory accident, a so called “laboratory-acquired infection”, in Wuhan, China. The briefing was also to include a discussion by David Asher, a senior fellow at the Hudson Institute, about his work at the U.S. State Department looking into the origins of COVID-19 and the role of the Chinese government. Dr. Quay recently stated, “While it would be a positive step for China to be open and transparent with records from the Wuhan Institute of Virology that were not shared with the WHO Committee during their field work in China earlier this year, there already exists more than enough data and evidence to conclude with high certainty that the COVID pandemic did not arise from a natural zoonosis. The purpose of this briefing is to supply relevant congressional staff and members with the facts that are not in dispute with respect to the pandemic, to show how these facts are different from any prior zoonosis, to show these facts are completely consistent with a lab-leak, and finally, to document the genetic signatures that are consistent with ‘gain-of-function’ laboratory manipulation. For over a year there has been a reticence to consider a lab-leak as the source of this pandemic despite the fact that most of the evidence I will present has been in the public domain all this time. It is clear to me that only a grass roots effort directed to the federal government will bring the urgency to help uncover the cause of the pandemic and set the stage to put in place the safeguards to prevent the next. You can help in this fight by inviting your Representative and Senators to this briefing on the leading COVID origin hypothesis, the possibility of a laboratory acquired infection at the Wuhan Institute of Virology. We owe it to the three million people who have died to get to the bottom of this.”
    • On May 14, Atossa announced financial results for the fiscal quarter ended March 31, 2021, and provided an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “During the first quarter of 2021 we continued our two key development programs, namely our Phase 2 study of oral Endoxifen for the ‘window of opportunity’ between diagnosis of breast cancer and surgery and our Phase 1 study of AT-301 nasal spray for at-home use for patients recently diagnosed with COVID-19. In addition, we continued our ongoing expanded access program with Endoxifen in which the drug continues to be well tolerated and breast cancer recurrence has not been seen clinically. We also received an important authorization from the FDA for an additional expanded access treatment program in an ovarian cancer patient. Combined with very encouraging results in our COVID-19 program with AT-301 nasal spray, we continued to make great progress over the quarter. In the meantime, we leveraged favorable conditions in the capital markets to strengthen our balance sheet over the last few months placing Atossa in a good position to execute on these and potential additional business opportunities during the remainder of 2021. As a result, we are diligently moving our existing programs forward, while actively exploring the possibility for strategic expansion into other areas where we might see near-term milestones and results. We look forward to continuing to update our stockholders on these opportunities as they develop.
  •  
  • Shares of  INVO Bioscience, Inc. (INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $4.31.
  • Could we be setting up for another March 9, 2021 type of run for INVO shares where +96M shares traded for this low-float stock (~10.4M shares are issued and outstanding). This is also when the stock shot up to a new 52-week high of $12.30….  The stock has again continued to trend upwards since May 11th.  See INVO’s chart on here. 
    • On May 17, INVO announced financial results for the first quarter of 2021 ended March 31, 2021 and provides a business update. Steve Shum, Chief Executive Officer of INVO Bioscience stated, “This was an exciting start to the year 2021 for INVO Bioscience as we advanced our INVO Clinic strategy with the signing of our first U.S.-based INVOcell exclusive facility in Birmingham, Alabama, the signing of a partnership agreement to establish and operate a center in Northern California, and the completion of our product registration in Mexico. We expect these initial centers to become operational in the second half of the year. Throughout this year, we have expanded our real-world experience data and positive results with INVOcell, enhanced our online training tools, materials, and capabilities and have experienced a substantial increase in active training sessions for our international partners and distributors. We believe the combination of strong commercialization partnerships and company-owned clinics, both in the U.S. and around the world, is key to expanding INVOcell’s adoption within the fertility industry. In addition to the progress made executing new commercialization agreements, we have strengthened our marketing capabilities to support the INVOcell-only centers and our growing number of distribution partners. Meryle Lynn Chamberlain, a tenured women’s health and fertility solution marketing professional, joined us as Director of Marketing in March 2021, while Rebecca Messina, current Senior Advisor at McKinsey & Co. and former Global Chief Marketing Officer at both Uber and Beam Suntory joined our board of directors in April 2021. As we look to increase access to care and expand fertility treatment across the globe, our market positioning and overall strategies are more important than ever. The addition of Meryle Lynn and Rebecca will enhance our ability to successfully accomplish these goals. As we look to the remainder of 2021, we have set a number of key objectives, including the opening of our first company-owned clinics in Mexico and the United States. Additionally, we will seek to build our international revenues this year through our growing list of international distribution partners as they finish training, and we complete local product registration requirements. Of note, we are extremely pleased to see the initial INVO procedures performed recently in Spain and Malaysia, which reflects the groundwork done by our team in these specific markets, which we believe will help in further expanding the overall awareness of the potential outside of the U.S. Finally, we are continuing to advance our 5-day label expansion efforts with the FDA in the U.S. market with a goal of completing this effort in 2021. It remains our belief that there is strong global demand for fertility services and INVOcell is well-positioned through our growing, global footprint to play a key role in helping to turn the dream of creating a family for millions of people around the world into a reality through our accessible, efficient, and affordable fertility treatment.”
    • On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.



  • Shares of NeuBase Therapeutics (NBSE) closed trading this week at $5.29 slightly up from the $5.29 close last Friday. 
    • NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.
    • NeuBase will host a virtual R&D day for investors and analysts on Tuesday, June 8, 2021, from 12:30 p.m. to 2:30 p.m. EDT. During the event, NeuBase will present new data, along with an in-depth review of the Company’s pipeline of drug candidates – including in Huntington’s disease, myotonic dystrophy type 1, and a new oncology program for a target that has previously been thought of as undruggable – as well as an introduction to the expanded management team.

    • on May 13, NBSE reported its financial results for the three- and six-month periods ended March 31, 2021. Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase stated, “We continue to expand and scale our unique precision genetic medicine platform that we believe can turn genes on, off, or edit them in vivo, and thus address most mechanisms that cause diseases in a single industry-unifying solution. Our recent financing led by top-tier healthcare investors enables us to advance our lead program into the clinic next year and expand our pipeline to address historically undruggable oncogenic driver mutations. We look forward to hosting our R&D day on June 8th, during which we will present an update on our current pipeline programs, as well as introduce an oncology program targeting a genetic driver mutation in a high value indication.”


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Markets

Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  2. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius
  3. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  4. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  5. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  6. The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  7. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  8. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  9. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn
  10. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  11. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  12. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.”– Ike Skelton
  13. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson
  14. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  15. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  16. “Cash – in savings accounts, short-term CDs or money market deposits – is great for an emergency fund. But to fulfill a long-term investment goal like funding your retirement, consider buying stocks. The more distant your financial target, the longer inflation will gnaw at the purchasing power of your money.”  – Suze Orman
  17. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  18. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  19. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  20. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  21. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  22. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  23. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  24. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  25. “No stock price is too low for bears or too high for bulls.” –  John F. Heerdink, Jr.
  26. “Investment is most successful when it is most businesslike.” – Ben Graham
  27. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne
  28. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  29. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  30. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  31. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  32. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  33. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  34. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  35. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  36. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  37. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  38. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  39. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  40. “Know what you own, and know why you own it.” – Peter Lynch
  41. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  42. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz

  43. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  44. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel

  45. With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  46. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  47. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
  48. “Never depend on a single income, make an investment to create a second source.” Warren Buffet“Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.” ― Warren Buffett
  49. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  50. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  51. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  52. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  53. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  54. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  55. “The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  56. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  57. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  58. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  59. “In investing, what is comfortable is rarely profitable.” — Robert Arnott
  60. “Don’t look for the needle in the haystack. Just buy the haystack!” — John Bogle
  61. “No Price is too low for a bear or too high for a bull.” — Anonymous
  62. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” — Anonymous
  63. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  64. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  65. “If there is one common theme to the vast range of the world’s financial crises, it is that excessive debt accumulation, whether by the government, banks, corporations, or consumers, often poses greater systemic risks than it seems during a boom.” — Carmen Reinhart
  66. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  67. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  68. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  69. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  70. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
  71. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  72. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  73. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  74. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  75. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  76. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  77. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  78. “We always live in an uncertain world. What is certain is that the United States will go forward over time.” – Warren Buffett
  79. “Never test the depth of the river with both of your feet.” – Warren Buffet
  80. “Know what you own, and know why you own it.” – Peter Lynch
  81. “Liquidity is only there when you don’t need it.” -Old Proverb
  82. “There is no such thing as no risk. There’s only this choice of what to risk, and when to risk it.” – Nick Murray
  83. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  84. Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  85. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  86. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  87. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  88. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – PopeFrancis
  89. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  90. “Inaction and patience are almost always the wisest options for investors in the stock market.” – Guy Spier
  91. “Remember that the stock market is a manic depressive.”  – Warren Buffett
  92. “An investment in knowledge pays the best interest.” – Benjamin Franklin
  93. “I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  94. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  95. “The tax on capital gains directly affects investment decisions, the mobility and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  96. “If all the economists were laid end to end, they’d never reach a conclusion.
    -George Bernard Shaw
  97. “The riskiest thing we can do is just maintain the status quo. I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” – Bob Iger, Former Ceo of Disney
  98. “In the short run, the market is a voting machine. But in the long run, it is a weighing machine.” – Ben Graham
  99. “In investing, what is comfortable is rarely profitable.” -Robert Arnott
  100. “The fundamental law of investing is the uncertainty of the future.” -Peter Bernstein
  101. “How many millionaires do you know who have become wealthy by investing in savings accounts?” -Robert G Allen
  102. “Greed is all right, by the way. I think greed is healthy. You can be greedy and still feel good about yourself.”-Ivan Boesky
  103. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  104. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  105. “I talk about macro themes a lot because they are fun to talk about, but it is the risk management that is the most important thing. The risk control is all bottom-up. I structured the business right from the get-go so that we would have lots of diversification.” -Michael Platt
  106. “Blaming speculators as a response to financial crisis goes back at least to the Greeks. It’s almost always the wrong response.” -Larry Summers
Symbol Name Last Price Change % Change

Videos

Please consider viewing these interesting videos: